Welcome to the first global conference on DRESS Syndrome
Uniting researchers, medical professionals, and the DRESS community for learning and connection.
The Vanderbilt Office for Continuous Professional Development has approved the meeting for a maximum of 17.25 AMA PRA Category 1 Credit(s)TM.
DRESS Syndrome is a severe, adverse, hypersensitivity reaction to prescription drugs that causes life-threatening, progressive symptoms. The condition is also known as Drug-Induced Hypersensitivity Syndrome (DIHS).
One in every 1,000 to 10,000 medication exposures will result in DRESS. While most people recover from DRESS, 10% of patients will die from this disease.
By coming together in our first global and virtual DRESS Syndrome meeting, we aim to unite the research and medical communities with the DRESS Syndrome community and deepen our understanding of this relatively unknown condition.
If you are a DRESS survivor or have lost a loved one to DRESS Syndrome, we invite you to join us. Sharing your experiences will help contribute to the discussion on unmet clinical and research needs.
The conference is a virtual two-day event, and registration is complimentary.
Meeting highlights include:
- A DRESS Syndrome community-centered workshop
- New research presented by early investigators and trainees
- Plenary and keynote sessions
- Interactive discussions
- Themed chatrooms on a variety of DRESS topics
Posters from the medical and research communities due by October 24th.
Chairs
Elizabeth J. Phillips, MD, FIDSA, FAAAAI
Professor of Medicine, Dermatology, Pathology, Microbiology Professor of Pharmacology John A. Oates Chair in Clinical Research Center for Drug Safety and Immunology Vanderbilt University Medical Center
Dr. Phillips is a world leader in translational approaches to drug hypersensitivity and has pioneered the discovery and implementation of immunogenomic predictors, immunopathogenesis and novel technologies to improve the safety of drugs into clinical practice. She has a clinical practice dedicated to drug hypersensitivity and has led clinical and research programs in SJS/TEN and other severe immune-mediated adverse drug reactions across different medical systems for over 25 years. She is PI on NIH funded research to define genetic and other markers to lead to prediction and prevention earlier diagnosis and to define the most effective treatment. She has been a great advocate of integration and engagement of the community in science. In addition to being a Chair of SJSTEN 2021 she also founded and chaired the 2017 and 2019 meetings.
Roni P. Dodiuk-Gad, MD
Head, Inflammatory and Autoimmune Skin Diseases Unit, Dermatology Department, Emek Medical Center, Israel; Assistant Professor- Status Only, Department of Medicine, University of Toronto, Canada
Dr. Dodiuk-Gad is a clinician, researcher, educator, and opinion leader in Dermatology on the topics of adverse cutaneous drug reactions and Darier disease. She mentors students and residents both in Israel and Canada and leads several research teams focusing specifically on these topics. Dr. Dodiuk-Gad graduated from the Technion and conducted clinical and research fellowships in the University of Toronto. She is currently an Assistant Professor in both these institutes, the Head of the Dermatology Program Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Israel and the Head of Inflammatory and Autoimmune Skin Diseases Unit, Dermatology Department, Emek Medical Center, Israel. Dr. Dodiuk-Gad initiated several global educational platforms in Dermatology, and she is engaged in major international collaborations.
Rambi Cardones, MD, MHSc
Chief of Dermatology, Kansas University Medical Center
Dr. Adela Rambi G. Cardones is the Dermatology Division Chief and is a Tenured Professor at the University of Kansas Medical Center. She completed a research fellowship in immunology at the National Institutes of Health, in Bethesda MD, and her residency training in Dermatology at Duke University Medical Center. She received her Masters' Degree in Clinical Research through the Duke-NIH Clinical Research Training Program. She was the Director of Inpatient Dermatology at Duke University from 2010-2022, during which she also attained the rank of Tenured Associate Professor in the Department of Dermatology. Dr. Cardones has interest and expertise in Complex Medical Dermatology and Immunodermatology, including severe cutaneous drug reactions, autoimmune and fibrosing disorders, and graft-versus-host disease.
Conference Host
FAQ's
- Please make sure to have Google Chrome or Mozilla Firefox as a browser to use the platform and to view the sessions.
- It is recommended that you install ZOOM as an application on your compatible device in preparation of the meeting.
- A webcam is not required unless you are a speaker or panelist.
- A webcam will allow you to interact with other attendees during networking sessions and be visible if promoted to a panelist during the webinar Q&A section.
- Your login information is the email address and password you provided during registration. If you forget your password or have trouble with the login you can reach the support staff at dresssyndrome2022@getvfairs.io and assistance will be provided.
- Of note, prior to the event you will also receive an email from Vfairs with a direct link to the portal.
- Send an email to dresssyndrome2022@getvfairs.io for technical assistant.
- Yes, this is an online event only.
- You can participate from anywhere that you have Internet access.
- The event is accessible from desktop, mobile and tablet devices.
- Yes, you are welcome to invite others. You can simply share the link to this page https://dresssyndrome2022.vfairs.com/ and they can register at their convenience. Please be mindful that this event is focused on providing information to those that have survived DRESS syndrome, family members who have lost loved ones to DRESS, researchers who study DRESS syndrome, and healthcare providers who treat patients with DRESS.
- Our attendees and speakers are participating from several different time zones across the globe. Interaction is a key part of this meeting however if not possible for you to participate “live” all talks will be recorded (upon the speaker’s consent) and all talks and posters will be available on-demand for one month after the event is over on the conference website site.
- The live functions such as chat room will only be available during the virtual meeting.
- During and after the meeting you can also submit questions to the poster presenters through the Q&A function.
- The meeting takes place in US Central Time (CT). Please note, in the US daylight savings ends on November 6th. On Sunday, November 6, 2022, at 2:00 am clocks are turned backward one hour to Sunday, November 6, 2022, 1:00 am local standard time instead. Please click here to see the current US Central Time: https://time.is/CT .
- There will be two group chat rooms, one for community members to interact and another to interact with a DRESS expert. Advanced chat features such as one-on-one chat, voice, or video calls are also available. In addition, the DRESS Syndrome Foundation will have a booth within the exhibit hall to discuss & interact with attendees.
- There is a community members workshop that will take place November 5th from 12:00 pm to 2:00 pm CT.
- You will have an opportunity to ask questions of experts and interact with other community members in the virtual lounge.
- You will have opportunities to ask questions of the speakers following the live sessions.
- You can email us at drugsafetyresearch@vumc.org , and a member of our team will get back to you as soon as possible.
- You can also ask for technical assistance on the conference website if you have a question on the days of the conference.
Our Collaborators and Partners
DRESS Syndrome Foundation
DRESS Syndrome Foundation is a nonprofit dedicated to providing DRESS patients with medical advocacy and support. They also work to deepen medical research and awareness of this disease.
HHV-6 Foundation
HHV-6 Foundation is a nonprofit institution that encourages scientific exchange about HHV-6 infection between investigators by holding conferences, facilitating research, and offering pilot grants. They also raise awareness among physicians of other medical conditions associated with HHV-6 infection.
